Evidence map›Paper›PMID 29480176›Full record

ArticleJournal of Alzheimer's disease : JAD2018

Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions.

Christine M Burns, Alfred W Kaszniak, Kewei Chen, Wendy Lee, Daniel J Bandy, Richard J Caselli, Eric M Reiman

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. APOE and immunity: Research highlights.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Christine M BurnsMinneapolis Medical Research Foundation, Minneapolis, MN, USA.
Alfred W KaszniakDepartment of Psychology, University of Arizona, Tucson, AZ, USA.
Kewei ChenArizona Alzheimer's Consortium, Phoenix, AZ, USA.
Wendy LeeArizona Alzheimer's Consortium, Phoenix, AZ, USA.
Daniel J BandyArizona Alzheimer's Consortium, Phoenix, AZ, USA.
Richard J CaselliArizona Alzheimer's Consortium, Phoenix, AZ, USA.
Eric M ReimanArizona Alzheimer's Consortium, Phoenix, AZ, USA.
Alzheimer's Association · USArizona Alzheimer’s ConsortiumBanner Alzheimer’s InstituteOrthopaedic Research Foundation · USUniversity of Arizona · US

Funding

Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
PET, APOE & the Preclinical Course of Alzheimer's DiseaseR01AG031581 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI CASELLI, RICHARD J., REIMAN, ERIC MICHAEL · 2008 to 2018
$16.6M
PET, APOE, &THE PRECLINICAL COURSE OF ALZHEIMER DISEASER01MH057899 · NIMH · BANNER GOOD SAMARITAN MEDICAL CENTER · PI REIMAN, ERIC MICHAEL · 1998 to 2006
$5.2M
NIA NIH HHS P30 AG019610NIA NIH HHS R01 AG031581NIMH NIH HHS R01 MH057899
6 · The paper itself

Abstract

backgroundThe association between longitudinal changes in serum glucose level and longitudinal changes in [18F] Fluorodeoxyglucose-PET (FDG PET) measurements of Alzheimer's disease (AD) risk are unknown.

objectiveTo investigate whether variation in serum glucose levels across time are associated with changes in FDG PET measurements of cerebral metabolic rate for glucose (rCMRgl) in brain regions preferentially affected by Alzheimer's disease (AD).

methodsParticipants are a subset of a prospective cohort study investigating FDG PET, apolipoprotein E (APOE) ɛ4, and risk for AD which includes data from baseline, interim, and follow up visits over 4.4±1.0-years. An automated brain-mapping algorithm was utilized to characterize and compare associations between longitudinal changes in serum glucose levels and longitudinal changes in rCMRgl.

resultsThis study included 80 adults aged 61.5±5 years, including 38 carriers and 42 non-carriers of the APOE ɛ4 allele. Longitudinal increases in serum glucose levels were associated with longitudinal CMRgl decline in the vicinity of parietotemporal, precuneus/posterior cingulate, and prefrontal brain regions preferentially affected by AD (p < 0.05, corrected for multiple comparisons). Findings remained significant when controlled for APOE ɛ4 status and baseline and advancing age.

conclusionsAdditional studies are needed to clarify and confirm the relationship between longitudinal changes in peripheral glucose and FDG PET measurements of AD risk. Future findings will set the stage on the use of FDG PET in the evaluation of possible interventions that target risk factors for the development of AD.

Indexed as

AgedAlzheimer DiseaseApolipoprotein E4Blood GlucoseBrainBrain MappingFemaleFluorodeoxyglucose F18HeterozygoteHumansLongitudinal StudiesMaleMiddle AgedPositron-Emission TomographyProspective StudiesRadiopharmaceuticalsApolipoprotein E4Blood GlucoseFluorodeoxyglucose F18RadiopharmaceuticalsAlzheimer’s diseaseblood glucoselongitudinal studiespositron emission tomography

Identifiers

PMID29480176
PMCPMC6571123
OpenAlexW2794174359

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.